{"id":25983,"date":"2024-08-13T15:13:43","date_gmt":"2024-08-13T13:13:43","guid":{"rendered":"https:\/\/ggba.swiss\/release-therapeutics-secures-chf-3-3-million-to-advance-mld-research\/"},"modified":"2024-08-13T15:15:28","modified_gmt":"2024-08-13T13:15:28","slug":"release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/","title":{"rendered":"Release Therapeutics l\u00e8ve CHF 3,3 millions pour faire avancer la recherche sur la MLD"},"content":{"rendered":"\n

La soci\u00e9t\u00e9 genevoise Release Therapeutics<\/a>, fond\u00e9e en 2023, a obtenu un financement de d\u00e9marrage de CHF 3,3 millions de la part d’investisseurs priv\u00e9s \u00e0 la suite de la publication de ses r\u00e9sultats pr\u00e9cliniques sur la leucodystrophie m\u00e9tachromatique (MLD). La leucodystrophie m\u00e9tachromatique est une maladie g\u00e9n\u00e9tique d\u00e9vastatrice du syst\u00e8me nerveux qui touche le plus souvent les jeunes enfants \u00e2g\u00e9s de 12 \u00e0 20 mois. Cette maladie r\u00e9sulte d’un d\u00e9ficit de l’enzyme lysosomale arylsulfatase A (ARSA), ce qui entra\u00eene une grave d\u00e9t\u00e9rioration neurologique et, tragiquement, une esp\u00e9rance de vie de moins de cinq ans pour la plupart des enfants atteints.<\/p>\n\n\n\n

Release Therapeutics est \u00e0 l’origine d’une nouvelle technologie de macroencapsulation cellulaire con\u00e7ue pour d\u00e9livrer des prot\u00e9ines th\u00e9rapeutiques directement \u00e0 travers la barri\u00e8re h\u00e9mato-enc\u00e9phalique humaine. Cette technologie int\u00e8gre un dispositif de macroencapsulation implantable avec une lign\u00e9e de cellules myoblastes immortalis\u00e9es capable de produire une large gamme de prot\u00e9ines pour une administration \u00e0 long terme dans le syst\u00e8me nerveux central (SNC). Cette approche offre une nouvelle fa\u00e7on de traiter les maladies g\u00e9n\u00e9tiques telles que la MLD, sans avoir recours \u00e0 la th\u00e9rapie g\u00e9nique.<\/p>\n\n\n\n

La soci\u00e9t\u00e9 a r\u00e9cemment conclu une collaboration strat\u00e9gique avec l’Unit\u00e9 d’innovation en th\u00e9rapie g\u00e9nique et cellulaire (GENOV<\/a>) de l’Institut du cerveau de Paris afin de tester sa technologie sur des souris atteintes de MLD. Les souris ont \u00e9t\u00e9 implant\u00e9es avec un analogue du dispositif Myo-P de Release Therapeutics et ont re\u00e7u un traitement enzymatique substitutif ARSA pendant trois mois. De mani\u00e8re remarquable, les souris trait\u00e9es ont montr\u00e9 un renversement de la progression de la maladie, d\u00e9montrant le potentiel de cette technologie dans le traitement de la MLD symptomatique. Ces r\u00e9sultats prometteurs ont \u00e9t\u00e9 pr\u00e9sent\u00e9s au 20e Symposium mondial sur les troubles du stockage lysosomal par le Dr Fran\u00e7oise Piguet, directrice de GENOV.<\/p>\n\n\n\n

Le financement nouvellement obtenu permettra \u00e0 Release Therapeutics de faire progresser ses programmes de d\u00e9veloppement clinique, notamment en \u00e9valuant l’impact de sa technologie sur les primates non humains. Dans le communiqu\u00e9 de presse de l’entreprise, le CEO Thomas Mehrling a soulign\u00e9 l’importance de cette \u00e9tape : \u00ab Le financement d’amor\u00e7age t\u00e9moigne de l’importance de notre collaboration avec l’Institut du Cerveau de Paris et de nos d\u00e9couvertes dans le traitement de la MLD. Nous pr\u00e9voyons de lancer une lev\u00e9e de fonds de s\u00e9rie A au cours du dernier trimestre de cette ann\u00e9e afin de soumettre une demande d’IND et de faire entrer notre technologie en clinique le plus rapidement possible. \u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"

La soci\u00e9t\u00e9 Release Therapeutics a lev\u00e9 CHF 3,3 millions pour financer son approche innovante du traitement de la leucodystrophie m\u00e9tachromatique (MLD), une maladie g\u00e9n\u00e9tique rare qui touche les jeunes enfants.<\/p>\n","protected":false},"author":6,"featured_media":25980,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1188,1171,1142,1168],"class_list":["post-25983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-pharma-fr-2","tag-rd-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"\nRelease Therapeutics l\u00e8ve CHF 3,3M pour la recherche sur la MLD<\/title>\n<meta name=\"description\" content=\"Release Therapeutics a lev\u00e9 CHF 3,3 millions pour financer son approche innovante du traitement de la leucodystrophie m\u00e9tachromatique (MLD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Release Therapeutics l\u00e8ve CHF 3,3M pour la recherche sur la MLD\" \/>\n<meta property=\"og:description\" content=\"Release Therapeutics a lev\u00e9 CHF 3,3 millions pour financer son approche innovante du traitement de la leucodystrophie m\u00e9tachromatique (MLD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-13T13:13:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-13T13:15:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Release Therapeutics l\u00e8ve CHF 3,3 millions pour faire avancer la recherche sur la MLD\",\"datePublished\":\"2024-08-13T13:13:43+00:00\",\"dateModified\":\"2024-08-13T13:15:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/\"},\"wordCount\":474,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Pharma\",\"R&D\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/\",\"name\":\"Release Therapeutics l\u00e8ve CHF 3,3M pour la recherche sur la MLD\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg\",\"datePublished\":\"2024-08-13T13:13:43+00:00\",\"dateModified\":\"2024-08-13T13:15:28+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Release Therapeutics a lev\u00e9 CHF 3,3 millions pour financer son approche innovante du traitement de la leucodystrophie m\u00e9tachromatique (MLD).\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Avec des r\u00e9sultats attendus pour l'automne 2024, Release Therapeutics est bien positionn\u00e9e pour poursuivre sa mission de d\u00e9veloppement de traitements efficaces pour la MLD et d'autres maladies g\u00e9n\u00e9tiques.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Release Therapeutics l\u00e8ve CHF 3,3 millions pour faire avancer la recherche sur la MLD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Release Therapeutics l\u00e8ve CHF 3,3M pour la recherche sur la MLD","description":"Release Therapeutics a lev\u00e9 CHF 3,3 millions pour financer son approche innovante du traitement de la leucodystrophie m\u00e9tachromatique (MLD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/","og_locale":"fr_FR","og_type":"article","og_title":"Release Therapeutics l\u00e8ve CHF 3,3M pour la recherche sur la MLD","og_description":"Release Therapeutics a lev\u00e9 CHF 3,3 millions pour financer son approche innovante du traitement de la leucodystrophie m\u00e9tachromatique (MLD).","og_url":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-08-13T13:13:43+00:00","article_modified_time":"2024-08-13T13:15:28+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Release Therapeutics l\u00e8ve CHF 3,3 millions pour faire avancer la recherche sur la MLD","datePublished":"2024-08-13T13:13:43+00:00","dateModified":"2024-08-13T13:15:28+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/"},"wordCount":474,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg","keywords":["Biotech","Financing","Healthcare","Pharma","R&D","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/","url":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/","name":"Release Therapeutics l\u00e8ve CHF 3,3M pour la recherche sur la MLD","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg","datePublished":"2024-08-13T13:13:43+00:00","dateModified":"2024-08-13T13:15:28+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Release Therapeutics a lev\u00e9 CHF 3,3 millions pour financer son approche innovante du traitement de la leucodystrophie m\u00e9tachromatique (MLD).","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/MLD-Release-Therapeutics-1180x811-1.jpg","width":1180,"height":811,"caption":"Avec des r\u00e9sultats attendus pour l'automne 2024, Release Therapeutics est bien positionn\u00e9e pour poursuivre sa mission de d\u00e9veloppement de traitements efficaces pour la MLD et d'autres maladies g\u00e9n\u00e9tiques."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/release-therapeutics-leve-chf-33-millions-pour-faire-avancer-la-recherche-sur-la-mld\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Release Therapeutics l\u00e8ve CHF 3,3 millions pour faire avancer la recherche sur la MLD"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=25983"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25983\/revisions"}],"predecessor-version":[{"id":25985,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/25983\/revisions\/25985"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/25980"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=25983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=25983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=25983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}